Betty Tyler Selected Research

Carmustine (FIVB)

10/2021	Pharmacological strategies for improving the prognosis of glioblastoma.
11/2019	Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumor.
10/2019	Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
1/2015	Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy.
2/2008	A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.
11/2005	Local delivery of doxorubicin for the treatment of malignant brain tumors in rats.
8/2005	In vivo delivery of BCNU from a MEMS device to a tumor model.
11/2004	In vivo release from a drug delivery MEMS device.
10/2004	Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
2/2002	Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Betty Tyler Research Topics

Disease

49	Neoplasms (Cancer) 03/2022 - 02/2002
41	Glioma (Gliomas) 02/2022 - 02/2002
25	Brain Neoplasms (Brain Tumor) 03/2022 - 07/2002
18	Glioblastoma (Glioblastoma Multiforme) 03/2022 - 11/2005
10	Gliosarcoma 01/2022 - 02/2002
3	Melanoma (Melanoma, Malignant) 02/2022 - 05/2004
3	Wounds and Injuries (Trauma) 01/2021 - 01/2018
3	Hepatitis C 01/2020 - 01/2018
3	Breast Neoplasms (Breast Cancer) 01/2019 - 09/2007
2	Rhabdoid Tumor (Rhabdoid Tumors) 09/2021 - 01/2018
2	Infections 12/2020 - 01/2018
2	Neuroinflammatory Diseases 05/2020 - 06/2015
2	Hemorrhage 12/2012 - 08/2010
2	Renal Cell Carcinoma (Grawitz Tumor) 07/2011 - 09/2007
1	Hypoxia (Hypoxemia) 01/2022
1	Opioid-Related Disorders (Opiate Addiction) 01/2021
1	Medulloblastoma 01/2021
1	Pain (Aches) 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Nasopharyngeal Carcinoma 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019
1	Squamous Cell Carcinoma of Head and Neck 01/2019
1	Chordoma 08/2017

Drug/Important Bio-Agent (IBA)

12	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 10/2007
12	PolymersIBA 01/2018 - 02/2002
10	Pharmaceutical PreparationsIBA 12/2021 - 11/2002
10	Carmustine (FIVB)FDA Link 10/2021 - 02/2002
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2009
3	Glutamic Acid (Glutamate)FDA Link 02/2022 - 10/2013
3	poliferprosan 20 drug combination carmustine (Gliadel)FDA Link 10/2021 - 01/2015
3	Dendrimers (Dendrons)IBA 05/2020 - 06/2015
3	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 01/2018
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 12/2012
3	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2014 - 09/2005
3	Biomarkers (Surrogate Marker)IBA 06/2014 - 01/2011
2	Programmed Cell Death 1 ReceptorIBA 02/2022 - 12/2016
2	LuciferasesIBA 02/2022 - 06/2013
2	AcriflavineIBA 01/2022 - 11/2017
2	Poly(amidoamine)IBA 05/2020 - 06/2015
2	Hydroxyl RadicalIBA 05/2020 - 06/2015
2	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2019
2	Thymidine KinaseIBA 01/2020 - 02/2015
2	Drug CombinationsIBA 10/2019 - 01/2012
2	GuanosineIBA 01/2019 - 01/2018
2	Therapeutic UsesIBA 01/2018 - 01/2016
2	LigandsIBA 01/2018 - 06/2013
2	AntigensIBA 12/2016 - 01/2014
2	Monoclonal AntibodiesIBA 01/2016 - 01/2016
2	Alkylating AgentsIBA 01/2015 - 10/2004
2	AmidesIBA 06/2014 - 01/2011
2	Protons (Proton)IBA 06/2014 - 01/2011
2	Bevacizumab (Avastin)FDA Link 03/2014 - 07/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2013 - 11/2005
2	Tyrosine Kinase InhibitorsIBA 07/2013 - 01/2012
2	APTIBA 12/2012 - 01/2011
2	Interleukin-2 (IL2)IBA 11/2012 - 09/2005
2	CytokinesIBA 11/2012 - 05/2004
2	Antineoplastic Agents (Antineoplastics)IBA 08/2009 - 02/2002
2	CamptothecinIBA 10/2004 - 02/2002
2	Carboplatin (JM8)FDA LinkGeneric 01/2004 - 11/2002
1	Heterogeneous-Nuclear Ribonucleoprotein Group F-HIBA 03/2022
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 03/2022
1	Immune Checkpoint InhibitorsIBA 02/2022
1	Enhancer of Zeste Homolog 2 ProteinIBA 09/2021
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2021
1	Cyclin D1IBA 09/2021
1	14- methyl- 20- oxa- 5,7,14,26- tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaeneIBA 09/2021
1	Histone MethyltransferasesIBA 09/2021
1	Opioid Analgesics (Opioids)IBA 01/2021
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2021
1	Captopril (Capoten)FDA LinkGeneric 01/2021
1	CopperIBA 01/2021
1	Disulfiram (Antabuse)FDA Link 01/2021
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2021
1	TabletsIBA 01/2021
1	EndopeptidasesIBA 01/2021
1	Eukaryotic Initiation Factor-4EIBA 01/2020
1	poly(beta-amino ester)IBA 01/2020
1	Bromodeoxyuridine (BrdU)IBA 01/2020
1	Poly I-CIBA 04/2018
1	Coloring Agents (Dyes)IBA 11/2017
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 10/2017
1	Cisplatin (Platino)FDA LinkGeneric 10/2017
1	Caspase 3 (Caspase-3)IBA 10/2017
1	salicylhydroxamic acid (SHAM)IBA 08/2017
1	Brachyury protein (Brachyury)IBA 08/2017
1	Liposomes (Liposome)IBA 12/2016
1	Drug CarriersIBA 12/2016
1	MicellesIBA 12/2016
1	Nucleic AcidsIBA 10/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	Bone Morphogenetic Protein 4IBA 01/2016

Therapy/Procedure

31	Therapeutics 03/2022 - 07/2002
12	Drug Therapy (Chemotherapy) 11/2019 - 11/2002
9	Radiotherapy 01/2020 - 08/2010
5	Immunotherapy 02/2022 - 01/2014
1	Minimally Invasive Surgical Procedures 12/2020
1	Catheters 01/2018
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2016
1	Intravenous Administration 01/2016